Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-10-16
2007-10-16
Foley, Shanon (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S185100, C424S278100
Reexamination Certificate
active
10213145
ABSTRACT:
The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
REFERENCES:
patent: 4950574 (1990-08-01), Kumagai et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 5648376 (1997-07-01), Strobel et al.
patent: 5801193 (1998-09-01), Ojo-Amaize et al.
patent: 5817306 (1998-10-01), Haskill et al.
patent: WO98/39421 (1998-09-01), None
patent: WO99/35170 (1999-07-01), None
patent: WO 00/04140 (2000-01-01), None
patent: WO 00/12708 (2000-03-01), None
patent: WO 00/37640 (2000-06-01), None
patent: WO 00/73348 (2000-12-01), None
“Basic and Clinical Immunology,” 8thedition, 1994, pp. 30-31, 208-209, 246-247.
“Manual of Clinical Laboratory Immunology,” 6th Edition, 2002, ASM PRESS, pp. 1164-1166.
Kahan, B., Cur. Opin. Immunol. 4: 553-560, 1992.
Piccotti et al. (Transplantation 67: 1453-1460, 1999).
Campo et al. (Biological Trace Element Res. 79: 15-22, 2001).
Peterson et al., J. Clin. Oncol. 21:2342-2348, 2003.
Reddy et al, Infect. Immun. 44:339-343, 1984.
Pahwa et al, PNAS 86:5069-5073, 1989.
Kirchner et al. Br. J. Clin. Pharmacol. 46:5-10, 1998.
Chapoval et al, J. Immunol., 161:6977-6984.
Ma et al, J. Immunol. 171:608-615, 2003.
Tarr, P.E. Med. Oncol. 13:133-140, 1996.
Gennari et al. Annals of Surgery, 220:68-76, 1994.
Toura et al. J. Immunol. 163:2387-2391, 1999.
Tsavaris et al., Br. J. Cancer 87:21-27, 2002.
Amirghofran et al Im. J. Med. Sci. 25:119-124, 2000.
Abolhassani, M., Brazilian Journal of Infectious Diseases 8:382-385, 2004.
Kahan (Cur. Opin. Immunol. 4:553-560, 1992).
Piccotti et al (Transplantation 67:1453-1460, 1999).
Campo et al (Biological Trace Element Res. (79: 15-22, 2001).
Nastala et al (J. Immunol. 153:1697-1706, 1994).
Gura (Science, 1997, 278:1041-1042.).
Alderson et al., “Molecular and Biological Characterization of Human 4-1BB and Its Ligand.”European Journal of Immunology. 24(9):2219-2227 (Sep. 1994).
Bolton, C., “Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment.”Multiple Sclerosis. 1:143-149 (1995).
Chambers and Allison., “Co-Stimulation in T Cell Responses.”Current Opinion in Immunology. 9(3):396-404 (Jun. 1997).
Coligan et al, eds., “Proliferative Assays for T Cell Function”Current Protocols in Immunology, John Wiley & Sons, Inc., Chapter 3.12, vol. 1 (1994).
Coligan et al., eds.Current Protocols in Immunology., New York:John Wiley & Sons, Inc., Chapter 15.1, 15.2, (1994).
Coligan et al., eds., “Delayed-Type Hypersensitivity.”Current Protocols in Immunology., New York:John Wiley & Sons, Inc., Chapter 4.5, (1994).
Grabbe and Schwarz., “Immunoregulatory Mechanisms Involved in Elicitation of Allergic Contact Hypersensitivity.”Immun. Today. 19(1):37-44 (1998).
Hellstrom and Hellstrom., “T Cell Immunity to Tumor Antigens.”Critical Reviews in Immunology. 18(1-2):1-6 (1998).
Issekutz et al., “Treatment of Established Adjuvant Arthritis in Rats with Monoclonal Antibody to CD18 and Very Late Activation Antigen-4 Integrins Suppresses Neutrophil and T-Lymphocyte Migration to the Joints and Improves Clinical Disease.”Immunology. 88:569-576 (1996).
Jenkins, M., “The Ups and Downs of T Cell Costimulation.”Immunity. 1 (6):443-446 (Sep. 1994).
June et al., “The B7 and CD28 Receptor Families.”Immunology Today. 15(7):321-331 (Jul. 1994).
Linsley and Ledbetter., “The Role of the CD28 Receptor During T Cell Responses to Antigen.”Annu. Rev. Immunol. 11:191-212 (1993).
Schwartz, W., “Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy.”Cell. 71(7):1065-1068 (Dec. 24, 1992).
Tanabe et al., “Combined Immunosuppressive Therapy with Low Dose FK506 and Antimetabolites in Rat Allogenic Heart Transplantation.”Transplantation. 58(1):23-27 (1994).
Tinubu et al., “Humanized Antibody Directed to the IL-2 Receptor β-Chain Prolongs Primate Cardiac Allograft Survival.”J. Immunol. 153:4330-4338 (1994).
Walunas et al., “CTLA-4 Can Function as a Negative Regulator of T Cell Activation.”Immunity. 1(5):405-413 (Aug. 1994).
Wolyniec et al., “Reduction of Antigen-Induced Airway Hyperreactivity and Eosinophilia in ICAM-1-Deficient Mice.”Am. J. Respir. Cell Mol. Biol. 18:777-785 (1998).
Abolhassani, M., “Antibacterial effect of borage (Echium amoenum) onStaphylococcus aureus,” Brazilian Journal of Infectious Diseases 8:382-385 (2004).
Amirghofran, Z. et al., “Echium amoenumstimulate of lymphocyte proliferation and inhibit fo humoral antibody synthesis,”Im. J. Med. Sci. 25:119-124 (2000).
Chapoval, A. I. et al., “Combination chemotherapy and IL-15 administration induces permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells,”J. Immunol. 161:6977-6984 (1998).
Gennari, R. et al., “Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance,”Annals of Surgery 220:68-76 (1994).
Grabstein, K.H. et al., “Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor,”Science 264:965-968 (1994).
Kasaian, M.T. et al., “IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity,”Immunity 16:559-569 (2002).
Kirchner, G.I. et al., “Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application,”Br. J. Clin. Pharmacol. 46:5-10 (1998).
Ma, H-L et al., “IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent on INF-γ,”J. Immunol. 171:608-615 (2003).
Naito, K. et al., “Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells,”J. Immunol. 142:1834-1839 (1989).
Nastala, C.L. et al., “Recombinant IL-12 administration induces tumor regression in association with IFN-γ production,”J. Immunol. 153:1697-1706 (1994).
Pahwa, R. et al. “Recombinant interleukin 2 therapy in severe combined immunodeficiency disease,”Proc. Natl. Acad. Sci. USA 86:5069-5073 (1989).
Patterson, S. et al., “Human invariant NKT cells are required for effective in vitro alloresponses,”J. Immunol. 175:5087-5094 (2005).
Reddy, M.M. et al., “Interleukin 2 augmentation of natural killer cell activity in homosexual men with acquired immune deficiency syndrome,”Infect. Immunol. 44:339-343 (1984).
Santoli, D. et al., “Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules,”J. Immunol. 137:400-407 (1986).
Tarr, P.E. et al., “Granulocyte-macrophage colony-stimulating factor and the immune system,”Med Oncol. 13:133-140 (1996).
Toura, I. et al., “Cutting edge: Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide,”J. Immunol. 163:2387-2391 (1999).
Tsavaris, N. et al., “Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes,”Br. J. Cancer 87:21-27 (2002).
Goddard Audrey
Godowski Paul J.
Gurney Austin L.
Hillan Kenneth J.
Tumas Daniel
Aeder Sean E
Barnes Elizabeth M.
Dreger Ginger R.
Foley Shanon
Genentech Inc.
LandOfFree
Compositions and methods for the treatment of immune related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of immune related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of immune related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3898123